- NASDAQ:SRNE falls by 4.27% despite broader markets rising.
- Sorrento announces a positive Phase 1B for its injectable cancer pain treatment.
- Sorrento has also made headlines this year as a potential coronavirus vaccine candidate.
NASDAQ:SRNE has given back most of the profits from the 11% spike on Tuesday and has now fallen 17% over the past two days. Shares closed Thursday’s trading session down 4.27% hitting $9.19 per share, which is down over 50% from its 52-week highs. Needless to say, investors have not shown much confidence in Sorrento Therapeutics despite the San Diego based biotech firm being in the running for a potential coronavirus vaccine candidate earlier this year. While the stock has still returned over 350% over the past year, is struggling these days, currently trading below the 50-day moving average.
On Tuesday, Sorrento Therapeutics reported a successful Phase 1B from their clinical trials for its epidural resiniferatoxin or RTX injection, which is a prospective treatment for intractable cancer pain. The announcement was met with enthusiasm both from the medical community and from investors as the stock surged by 11% after the report. Wall Street analysts showed their optimism as the price target was raised to $21 by Dawson James and $30 by H.C. Wainwright. The median price target across all analysts is $24, which means that Sorrento may have quite a bit of upside heading into 2021.
SRNE stock news
The short and long-term outlook for Sorrento Therapeutics is indeed positive in the eyes of Wall Street, although investors have not been as supportive since the RXT announcement. While it does seem like there are some larger biotech firms who are ahead of Sorrento in the coronavirus vaccine race, the successful report of its cancer pain treatment is positive news for those who have been on the fence about investing in the company.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD edges lower toward 1.0700 post-US PCE
EUR/USD stays under modest bearish pressure but manages to hold above 1.0700 in the American session on Friday. The US Dollar (USD) gathers strength against its rivals after the stronger-than-forecast PCE inflation data, not allowing the pair to gain traction.
GBP/USD retreats to 1.2500 on renewed USD strength
GBP/USD lost its traction and turned negative on the day near 1.2500. Following the stronger-than-expected PCE inflation readings from the US, the USD stays resilient and makes it difficult for the pair to gather recovery momentum.
Gold struggles to hold above $2,350 following US inflation
Gold turned south and declined toward $2,340, erasing a large portion of its daily gains, as the USD benefited from PCE inflation data. The benchmark 10-year US yield, however, stays in negative territory and helps XAU/USD limit its losses.
Bitcoin Weekly Forecast: BTC’s next breakout could propel it to $80,000 Premium
Bitcoin’s recent price consolidation could be nearing its end as technical indicators and on-chain metrics suggest a potential upward breakout. However, this move would not be straightforward and could punish impatient investors.
Week ahead – Hawkish risk as Fed and NFP on tap, Eurozone data eyed too
Fed meets on Wednesday as US inflation stays elevated. Will Friday’s jobs report bring relief or more angst for the markets? Eurozone flash GDP and CPI numbers in focus for the Euro.